In the context of neurodegenerative disorders, such as Alzheimer's disease (AD), the measurement of blood GFAP has demonstrated heightened efficacy compared to CSF levels in capturing amyloid-β (Aβ) pathology, particularly in the initial stages of the AD spectrum [44]. The gene discussed is GFAP; the disease is Alzheimer disease.